Back to Journals » Cancer Management and Research » Volume 7

Progress toward overcoming hypoxia-induced resistance to solid tumor therapy

Authors Karakashev S, Reginato M

Received 9 May 2015

Accepted for publication 14 June 2015

Published 12 August 2015 Volume 2015:7 Pages 253—264


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Kenan Onel

Video abstract presented by Sergey V Karakashev.

Views: 1579

Sergey V Karakashev, Mauricio J Reginato

Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USA

Abstract: Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance.

Keywords: HIF-1, cancer, chemoresistance, signaling, apoptosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]